

April 7, 1966

Dr. Ivan F. Bennett
The Lilly Research Laboratories
Eli Lilly and Company
RR 18, Box 285
Indianapolis, Indiana

Dear Ivan,

I very much enjoyed our luncheon in Washington, and while I do not think that further studies with cycloserine as a therapeutic agent in schizophrenia are warranted, its possible use as a central stimulant still intrigues us. We are now collating the data of our study and find that my notes are confused in one regard. I am writing to ask your clarification.

According to the *Physicians Desk Reference*, Seromycin is neither the D nor the L form. Seromycin combined with isoniazid is listed as D-4-amino-3-isoxazolidinone. We had interpreted the D before this chemical name as indicating that it was the D form that appeared in Seromycin. The articles written by George Crane also list his use of D form. In our discussion, I believe you indicated that Seromycin is the mixture.

Can you clarify which form we have been using? Also, I have misplaced the product description and would request your sending me another if it is available.

Many thanks.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp